Patents Examined by Shin-Lin Chen
-
Patent number: 11357800Abstract: Without limitation, a method for preventing and/or treating neuropathic pain in a subject/patient comprising administering a therapeutically effective amount of exosomes derived and isolated from mammalian cells to the subject/patient and a method of treating cancer in a subject/patient in need thereof, comprises administering a combination comprising a therapeutically effective amount of exosomes derived and isolated from mammalian cells and a chemotherapeutic agent.Type: GrantFiled: August 16, 2017Date of Patent: June 14, 2022Assignee: Henry Ford Health SystemInventors: Zhenggang Zhang, Yi Zhang, Michael Chopp
-
Patent number: 11351270Abstract: Truncated junctophilin-2 related proteins, transcriptional repressor domains, vectors encoding the proteins or domains, and methods of using the proteins and domains, are provided.Type: GrantFiled: June 7, 2017Date of Patent: June 7, 2022Assignee: University of Iowa Research FoundationInventors: Long-Sheng Song, Ang Guo
-
Patent number: 11352641Abstract: Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5? homology arm, b.) a 3? group I intron fragment containing a 3? splice site dinucleotide, c.) optionally, a 5? spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3? spacer sequence, f) a 5? Group I intron fragment containing a 5? splice site dinucleotide, and g.) a 3? homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.Type: GrantFiled: September 7, 2021Date of Patent: June 7, 2022Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Daniel G. Anderson, Robert Alexander Wesselhoeft, Piotr S. Kowalski
-
Patent number: 11352640Abstract: Methods and constructs for engineering circular RNA are disclosed. In some embodiments, the methods and constructs comprise a vector for making circular RNA, the vector comprising the following elements operably connected to each other and arranged in the following sequence: a.) a 5? homology arm, b.) a 3? group I intron fragment containing a 3? splice site dinucleotide, c.) optionally, a 5? spacer sequence, d.) a protein coding or noncoding region, e.) optionally, a 3? spacer sequence, f.) a 5? Group I intron fragment containing a 5? splice site dinucleotide, and g.) a 3? homology arm, the vector allowing production of a circular RNA that is translatable or biologically active inside eukaryotic cells. Methods for purifying the circular RNA produced by the vector and the use of nucleoside modifications in circular RNA produced by the vector are also disclosed.Type: GrantFiled: July 13, 2021Date of Patent: June 7, 2022Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Daniel G. Anderson, Robert Alexander Wesselhoeft, Piotr S. Kowalski
-
Patent number: 11351200Abstract: Described herein are compositions and methods related to use of exosomes, including cardiosphere derived cell (CDC)-derived exosomes for treatment and prevention of heart related disease and conditions, such as ventral arrhythmias, such as tachycardias. CDC-derived exosomes delivered by endocardial injection can diminish the total amount of isolated late potentials associated with an isthmus of slow conduction, while reducing the isoelectric interval between late abnormal ventricular activity and decreasing the incidence of inducible ventricular arrhythmias, thereby providing a biological treatment for arrhythmias which otherwise requires therapeutic interventions with adverse effects.Type: GrantFiled: June 2, 2017Date of Patent: June 7, 2022Assignee: Cedars-Sinai Medical CenterInventors: Eduardo Marban, Eugenio Cingolani, James Dawkins
-
Patent number: 11344608Abstract: The invention relates to a new, more potent, coagulation Factor IX (FIX) expression cassette for gene therapy of Haemophilia B (HB). Disclosed is a vector for expressing factor IX protein, the vector comprising a promoter, a nucleotide sequence encoding for a functional factor IX protein, and an intron sequence, wherein the intron sequence is positioned between exon 1 and exon 2 of the nucleotide sequence encoding for a functional factor IX protein, and wherein the intron sequence has at least 80% identity to the sequence of SEQ ID NO. 1 as disclosed herein.Type: GrantFiled: September 6, 2019Date of Patent: May 31, 2022Assignee: UCL BUSINESS LTDInventors: Amit Nathwani, Jenny Mcintosh, Nishil Patel
-
Patent number: 11332750Abstract: The present invention provides an expression system for a eukaryotic host, which comprises 1) an expression cassette comprising a core promoter, the core promoter controlling the expression of a DNA sequence encoding a synthetic transcription factor (sTF), and 2) one or more expression cassettes each comprising a DNA sequence encoding a desired product operably linked to a synthetic promoter, the synthetic promoter comprising a core promoter, and sTF-specific binding sites upstream of the core promoter. The present invention also provides a method for identifying universal core promoters for eukaryotic hosts, expression systems using universal core promoters, hosts comprising the systems, and methods for producing protein products in eukaryotic hosts.Type: GrantFiled: February 21, 2017Date of Patent: May 17, 2022Assignee: Teknologian Tutkimuskeskus VTT OYInventors: Dominik Mojzita, Anssi Rantasalo, Jussi Jäntti, Christopher Landowski, Joosu Kuivanen
-
Patent number: 11332756Abstract: RNA virus vectors comprising a gene encoding the DNA-dependent activator of interferon-regulatory factors (DAI) protein, and optionally further comprising a gene encoding the receptor-interacting serine/threonine-protein kinase 3 (RIPK3) may be used therapeutically to induce cell death, as well as an inflammatory immune response, against tumors and virally-infected cells.Type: GrantFiled: July 5, 2017Date of Patent: May 17, 2022Assignee: Institute For Cancer ResearchInventors: Siddharth Balachandran, Roshan Thapa
-
Patent number: 11317611Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanized programmed death-ligand 1 (PD-L1, PDL1, or B7-H1). Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous PD-L1 gene so that the non-human animals express a humanized PD-L1 protein that includes a human portion and an endogenous portion (e.g., a non-human portion).Type: GrantFiled: August 30, 2017Date of Patent: May 3, 2022Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.Inventors: Yuelei Shen, Yang Bai, Yanan Guo, Rui Huang, Xiaofei Zhou, Chaoshe Guo
-
Patent number: 11311583Abstract: The invention provides methods of reducing or decreasing a size of a tumor or eliminating a tumor by inhibiting, decreasing, or reducing neo-vascularization or angiogenesis in a tumor in a patient by administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter. Also provided is a homogeneous population of an adenovirus comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and its uses thereof.Type: GrantFiled: July 23, 2018Date of Patent: April 26, 2022Assignee: Vascular Biogenetics Ltd.Inventors: Eyal Breitbart, Andrea Leubitz, Erez Feige, Richard Penson
-
Patent number: 11311634Abstract: The present invention relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as SMA and ALS as well as Pompe disease and lysosomal storage disorders. It is disclosed that administration of a non-ionic, low-osmolar contrast agent, together with a rAA9 vector for the expression of Survival Motor Neuron protein, improves the survival of SMN mutant mice as compared to the administration of the expression vector alone.Type: GrantFiled: January 14, 2019Date of Patent: April 26, 2022Assignees: NATIONWIDE CHILDREN'S HOSPITAL, OHIO STATE INNOVATION FOUNDATIONInventors: Brian K. Kaspar, Arthur Burghes, Paul Porensky
-
Patent number: 11306328Abstract: Methods are provided for altering target DNA in a cell genetically modified to express a Cas 9 enzyme that forms a co-localization complex with a guide RNA complementary to the target DNA and that cleaves the target DNA in a site specific manner. Methods include introducing into the cell a first foreign nucleic acid encoding a donor nucleic acid sequence, introducing into the cell from media surrounding the cell the guide RNA complementary to the target DNA and which guides the Cas 9 enzyme to the target DNA, wherein the RNA and the enzyme are members of a co-localization complex for the target DNA, wherein the donor nucleic acid sequence is expressed, wherein the guide RNA and the Cas 9 enzyme co-localize to the target DNA, the Cas 9 enzyme cleaves the target DNA and the donor nucleic acid is inserted into the target DNA to produce altered DNA in the cell.Type: GrantFiled: June 30, 2014Date of Patent: April 19, 2022Assignee: President and Fellows of Harvard CollegeInventors: George M. Church, Luhan Yang, Marc Guell, Joyce Lichi Yang
-
Patent number: 11297811Abstract: The present invention relates to humanisation of antibodies in vivo. The invention provides non-human vertebrates, cells, populations and methods useful for humanising chimaeric antibodies in vivo. Using the present invention it is possible straightforwardly and rapidly to obtain antigen-specific antibodies that are fully human (ie, comprising human variable and constant regions) and have undergone recombination, junctional diversification, affinity maturation and isotype switching in vivo in a non-human vertebrate system. Furthermore, such antibodies are humanised (eg, totally human)—and selected—totally in vivo, and as such the present invention harnesses in vivo filtering for expressibility, affinity and biophysical characteristics in the context of the desired human variable and constant region pairings. This is avoids problems of down-grading antibody characteristics when humanising the constant region of chimaeric antibodies in vitro.Type: GrantFiled: March 14, 2019Date of Patent: April 12, 2022Assignee: Kymab LimitedInventor: Jasper Clube
-
Patent number: 11297810Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising the antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in the methods.Type: GrantFiled: March 7, 2019Date of Patent: April 12, 2022Assignee: Kymab LimitedInventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Dominik Spensberger, Hui Liu, Jasper Clube
-
Patent number: 11286461Abstract: Methods for improving the functionality and/or fertility of sperm, for example, by enhancing motility and/or extending the lifespan of sperm by subjecting the isolated sperm to a starvation protocol and/or ionophore are provided. Such methods may be used in, for example, artificial insemination to reduce the number of sperm needed for insemination and to improve conception rates.Type: GrantFiled: March 31, 2017Date of Patent: March 29, 2022Assignee: University of MassachusettsInventors: Pablo E. Visconti, Felipe Navarrete
-
Patent number: 11272695Abstract: The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) programmed cell death protein 1 (PD-1), and methods of use thereof. In one aspect, the animals have an insertion of a sequence encoding a human or humanized programmed cell death protein 1 (PD-1) at an endogenous PD-1 gene locus. This animal model can express a PD-1 protein containing a functional domain of the human PD-1 protein, and can be used as an animal model for developing therapeutics for human diseases and disorders, and assessing the toxicity and/or the efficacy of these human therapeutics.Type: GrantFiled: June 10, 2019Date of Patent: March 15, 2022Assignee: Biocytogen Pharmaceuticals (Beijing) Co., Ltd.Inventors: Yuelei Shen, Yanan Guo, Yang Bai, Rui Huang, Xiaofei Zhou, Meiling Zhang, Jiawei Yao, Chaoshe Guo
-
Patent number: 11268070Abstract: Methods are disclosed for reprogramming a somatic cell, including an adherent cell and a cell in suspension, into an induced pluripotent stem comprising expressing exogenous Sox-2, exogenous Klf-4, exogenous Oct3/4 from DNA that has not integrated into the genome of the somatic cell, suppressing p53 activity within the somatic cell, and exposing the somatic cell to reprogramming-assistance factors comprising an exogenous Alk-5 inhibitor, an exogenous histone deacetylase inhibitor, and an exogenous activator of glycolysis. Compositions and kits for use in such methods are also disclosed as are cells made by such a method.Type: GrantFiled: April 16, 2018Date of Patent: March 8, 2022Assignee: CELLULAR ENGINEERING TECHNOLOGIES, INC.Inventors: Alan B. Moy, Anant Kamath
-
Patent number: 11268088Abstract: This invention relates to compositions of matter, methods, modules and instruments for automated mammalian cell growth and mammalian cell transduction followed by nucleic acid-guided nuclease editing in live mammalian cells. The present compositions and methods entail viral delivery of an editing cassette to live mammalian cells such that the editing cassettes edit the cells and the edited cells continue to grow, preferably using a fully-automated end-to-end instrument to process the cells without human intervention to enhance cell processing uniformity and to maintain the integrity of the cell culture.Type: GrantFiled: April 23, 2021Date of Patent: March 8, 2022Assignee: Inscripta, Inc.Inventors: Phillip Belgrader, Christian Siltanen, William Watterson, Burak Dura, Bruce Chabansky, David Stumbo, Eric Smith, Jorge Bernate
-
Patent number: 11261430Abstract: Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE).Type: GrantFiled: May 3, 2017Date of Patent: March 1, 2022Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATIONInventors: George Q. Daley, Ryohichi Sugimura
-
Patent number: 11261432Abstract: The present invention provides a method of treating a disorder using a fibromodulin (FMOD) reprogrammed (FReP) cell. The method comprises administering locally to a human being the FReP cell to a site in need thereof of the human being.Type: GrantFiled: December 19, 2016Date of Patent: March 1, 2022Assignee: The Regents of the University of CaliforniaInventors: B. Chia Soo, Kang Ting, Zhong Zheng